Pembrolizumab
- Generic Name
- Pembrolizumab
- Brand Names
- Keytruda
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1374853-91-4
- Unique Ingredient Identifier
- DPT0O3T46P
- Background
Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes 4 ...
- Indication
Pembrolizumab is indicated for the following conditions:
For all approved adult indications, pembrolizumab may be used for an additional 6 weeks at 400mg weekly.
- Associated Conditions
- Advanced Endometrial Cancer, Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced or Metastatic Urothelial Carcinoma (UC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Cervical Cancer, Metastatic Esophageal Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Metastatic Triple Negative Breast Cancers, Metastatic Urothelial Carcinoma (UC), Metastatic cutaneous squamous cell carcinoma, Metastic Renal Cell Carcinoma, Non-Small Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage II, Persistent Cervical Cancer, Recurrent Cervical Cancer, Refractory Primary Mediastinal Large B-Cell Cell Lymphoma, Renal Cell Carcinoma (RCC), Resectable Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIB Melanoma, Stage IIC Melanoma, Stage III Melanoma, Stage IIIA Non Small Cell Lung Cancer, Unresectable Melanoma, Advanced Microsatellite Instability High Endometrial Carcinoma, Advanced Mismatch Repair-deficient (dMMR) Endometrial Carcinoma, High risk, early Triple Negative Breast Cancer, High risk, in situ Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG, Locally advanced Adenocarcinomas of the Gastroesophageal Junction, Locally advanced Esophageal Carcinoma, Locally advanced Urothelial Carcinoma, Metastatic HER2-positive Adenocarcinoma of the Stomach, Metastatic HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Metastatic High Tumor Mutation Burden Solid Tumors, Metastatic Merkel Cell Carcinoma (MCC), Metastatic Microsatellite Instability High Colorectal Cancer, Metastatic Microsatellite Instability-High (MSI-H) Solid Tumors, Metastatic Mismatch Repair Deficient Colorectal Cancer, Metastatic Mismatch repair deficient (dMMR) solid tumors, Recurrent Cutaneous Squamous Cell Carcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent, locally advanced Adenocarcinomas of the Gastroesophageal Junction, Recurrent, locally advanced Merkel Cell Carcinoma, Refractory Classical Hodgkin's Lymphoma, Relapsed Classical Hodgkin's Lymphoma, Stage 3 Non-Small Cell Lung Carcinoma (NSCLC), Unresectable High Tumor Mutation Burden Solid Tumors, Unresectable Microsatellite Instability High Colorectal Cancer, Unresectable Microsatellite Instability-High (MSI-H) Solid Tumors, Unresectable Mismatch Repair Deficient Colorectal Cancer, Unresectable Mismatch repair deficient (dMMR) solid tumors, Unresectable, locally advanced HER2-positive Adenocarcinoma of the Stomach, Unresectable, locally advanced HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Unresectable, locally recurrent Triple Negative Breast Cancer, Unresectable, recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Associated Therapies
- -
Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2015-10-14
- Last Posted Date
- 2017-09-27
- Lead Sponsor
- Gradalis, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT02574533
- Locations
- 🇺🇸
Texas Oncology P.A., Texas Cancer Center, Abilene, Texas, United States
🇺🇸Mary Crowley Medical Research Centers, Dallas, Texas, United States
🇺🇸Cancer Care Northwest, Spokane, Washington, United States
GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2015-10-14
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 36
- Registration Number
- NCT02575404
- Locations
- 🇺🇸
Providence Cancer Center, Portland, Oregon, United States
Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Viralytics
- Target Recruit Count
- 36
- Registration Number
- NCT02565992
- Locations
- 🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸John Wayne Cancer Institute, Santa Monica, California, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC)
- Conditions
- Interventions
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 41
- Registration Number
- NCT02564380
- Locations
- 🇩🇪
LungenClinic Grosshansdorf, Großhansdorf, Germany
A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 56
- Registration Number
- NCT02563548
- Locations
- 🇺🇸
Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Trial of Pembrolizumab and Radiotherapy in Melanoma
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 234
- Registration Number
- NCT02562625
- Locations
- 🇬🇧
Royal Marsden, London, United Kingdom
Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)
- Conditions
- Interventions
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 307
- Registration Number
- NCT02563002
Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 34
- Registration Number
- NCT02560636
- Locations
- 🇬🇧
NIHR Biomedical Research Centre at RM and ICR (https://www.cancerbrc.org/), Sutton, United Kingdom
PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma
- First Posted Date
- 2015-09-23
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Provectus Biopharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT02557321
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Pembro/Carbo/Taxol in Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Daniela Matei, MD
- Target Recruit Count
- 46
- Registration Number
- NCT02549209
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸Northwestern University, Robert H. Lurie Cancer Center, Chicago, Illinois, United States
🇺🇸Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.